LB Pharmaceuticals Inc
LBRX21.965USD
-0.185-0.83%
Market hours （ET）Quotes delayed by 15 min
555.70MMarket Cap
LossP/E TTM
More Details of LB Pharmaceuticals Inc Company
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
LB Pharmaceuticals Inc Info
Ticker SymbolLBRX
Company nameLB Pharmaceuticals Inc
IPO dateSep 11, 2025
CEOTurner (Heather D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endSep 11
AddressOne Pennsylvania Plaza, Suite 1025
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10119
Phone19174506581
Websitehttps://lbpharma.us/
Ticker SymbolLBRX
IPO dateSep 11, 2025
CEOTurner (Heather D)
Company Executives of LB Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
--
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
--
Dr. James Rawls
Dr. James Rawls
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Dr. Chen Yu, M.D.
Dr. Chen Yu, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Chief Executive Officer, Member of our Board of Director
Chief Executive Officer, Member of our Board of Director
--
--
Mr. Scott Garland
Mr. Scott Garland
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Rebecca Luse
Ms. Rebecca Luse
Independent Director
Independent Director
--
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
--
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
--
Dr. James Rawls
Dr. James Rawls
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Dr. Chen Yu, M.D.
Dr. Chen Yu, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.25%
RA Capital Management, LP
7.02%
TCG Crossover Management, LLC
6.90%
Commodore Capital LP
5.93%
Pontifax Venture Capital
5.58%
Other
61.32%
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.25%
RA Capital Management, LP
7.02%
TCG Crossover Management, LLC
6.90%
Commodore Capital LP
5.93%
Pontifax Venture Capital
5.58%
Other
61.32%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.38%
Venture Capital
24.96%
Investment Advisor
13.61%
Investment Advisor/Hedge Fund
10.18%
Institution
2.64%
Research Firm
1.70%
Individual Investor
0.31%
Bank and Trust
0.09%
Other
9.15%
Institutional Shareholding
Updated: Tue, Sep 23
Updated: Tue, Sep 23
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
10
12.02M
47.50%
+12.02M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deep Track Capital LP
3.35M
14.94%
+3.35M
--
Sep 12, 2025
RA Capital Management, LP
1.68M
7.46%
+1.68M
--
Sep 12, 2025
TCG Crossover Management, LLC
1.75M
7.78%
+1.75M
--
Sep 12, 2025
Commodore Capital LP
1.23M
5.46%
+1.23M
--
Sep 11, 2025
Pontifax Venture Capital
1.41M
6.29%
+1.41M
--
Sep 12, 2025
VV Manager LLC
883.68K
3.94%
+883.68K
--
Sep 12, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of LB Pharmaceuticals Inc?
The top five shareholders of LB Pharmaceuticals Inc are:
Deep Track Capital LP holds 3.35M shares, accounting for 14.94% of the total shares.
RA Capital Management, LP holds 1.68M shares, accounting for 7.46% of the total shares.
TCG Crossover Management, LLC holds 1.75M shares, accounting for 7.78% of the total shares.
Commodore Capital LP holds 1.23M shares, accounting for 5.46% of the total shares.
Pontifax Venture Capital holds 1.41M shares, accounting for 6.29% of the total shares.
Deep Track Capital LP holds 3.35M shares, accounting for 14.94% of the total shares.
RA Capital Management, LP holds 1.68M shares, accounting for 7.46% of the total shares.
TCG Crossover Management, LLC holds 1.75M shares, accounting for 7.78% of the total shares.
Commodore Capital LP holds 1.23M shares, accounting for 5.46% of the total shares.
Pontifax Venture Capital holds 1.41M shares, accounting for 6.29% of the total shares.
What are the top three shareholder types of LB Pharmaceuticals Inc?
The top three shareholder types of LB Pharmaceuticals Inc are:
Deep Track Capital LP
RA Capital Management, LP
TCG Crossover Management, LLC
Deep Track Capital LP
RA Capital Management, LP
TCG Crossover Management, LLC
How many institutions hold shares of LB Pharmaceuticals Inc (LBRX)?
As of 2025Q3, 10 institutions hold shares of LB Pharmaceuticals Inc, with a combined market value of approximately 12.02M, accounting for 47.50% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for LB Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for LB Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
